A randomized phse II study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Idiopathic pulmonary fibrosis; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms J-SONIC
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 15 May 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 New trial record